FAQ

GYKI 14451

Known as: GYKI 14,451, GYKI-14,451, GYKI-14451 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1980-1994
0119801994

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1994
1994
Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin.
Newly developed synthetic and recombinant thrombin inhibitors possess strong anticoagulant effects. Despite these effects… (More)
Is this relevant?
1992
1992
In vitro inhibition of blood coagulation by tripeptide aldehydes--a retrospective screening study focused on the stable D-MePhe-Pro-Arg-H.H2SO4.
A series of peptide aldehydes synthetized in our institute during the last 15 years were screened to detect their inhibitory… (More)
Is this relevant?
1990
1990
Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H.
D-Phe-Pro-Arg-H sulfate (GYKI-14166) is a highly active and selective inhibitor of thrombin both in vitro and in vivo. Recent… (More)
Is this relevant?
1982
1982
Design and synthesis of peptide inhibitors of blood coagulations.
Inhibition of blood coagulation by peptide aldehydes has been studied. Amino acid sequences were assembled from the P1-P2 portion… (More)
Is this relevant?
Review
1980
Review
1980
New strategies in the development of anti-atherosclerotic drugs.
The results of several recently completed trials of cardiovascular prevention, by the use of hypolipidemic or anti-platelet… (More)
Is this relevant?